TRIUMPH-2 is testing retatrutide in adults living with type 2 diabetes, and TRIUMPH-3 is looking at heart disease outcomes
Kopp KO, Glotfelty EJ, Li Y, Greig NH (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment
Patients treated with GLP-1 had about 55% lower odds of requiring transplant compared with those who underwent surgery
Commonly reported issues include nausea , diarrhea , and constipation , especially during the initial stages of treatment or when adjusting the dosage
Even experimental microneedle patches have yet to prove they can release consistent, therapeutically meaningful doses in humans
Anti-atherosclerosis Effects Atherosclerosis, a chronic inflammatory disorder of the arterial wall, involves several key contributors to its initiation and progression that can be favorably altered or attenuated by GLP-1 agonists